MYGN

Myriad Genetics, Inc. Healthcare - Diagnostics & Research Investor Relations →

YES
72.2% BELOW
↓ Approaching Was -71.9% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $16.49
14-Week RSI 25 📉
Rel. Volume (14w) This week's trading vs. the 14-week average 4.7x — Surging
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.09

Myriad Genetics, Inc. (MYGN) closed at $4.58 as of 2026-03-20, trading 72.2% below its 200-week moving average of $16.49. This places MYGN in the extreme value zone. The stock is currently moving closer to the line, down from -71.9% last week. With a 14-week RSI of 25, MYGN is in oversold territory.

A big spike in selling this week — 4.7x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.

Over the past 1541 weeks of data, MYGN has crossed below its 200-week moving average 28 times. On average, these episodes lasted 29 weeks. The average one-year return after crossing below was -10.8%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $428 million, MYGN is a small-cap stock. The company generates a free cash flow yield of 0.2%. Return on equity stands at -68.5%. The stock trades at 1.2x book value.

Share count has increased 15.1% over three years, indicating dilution.

Over the past 29.6 years, a hypothetical investment of $100 in MYGN would have grown to $81, compared to $1580 for the S&P 500. MYGN has returned -0.7% annualized vs 9.8% for the index, underperforming the broader market over this period.

Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: MYGN vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MYGN Crosses Below the Line?

Across 28 historical episodes, buying MYGN when it crossed below its 200-week moving average produced an average return of -11.8% after 12 months (median -16.0%), compared to +14.0% for the S&P 500 over the same periods. 39% of those episodes were profitable after one year. After 24 months, the average return was -9.0% vs +31.9% for the index.

Each line shows $100 invested at the moment MYGN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

MYGN has crossed below its 200-week MA 28 times with an average 1-year return of +-10.8% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Sep 1996Jan 19971813.3%-2.6%-17.5%
Apr 1997Jun 1997722.8%+4.0%-7.1%
Jun 1997Nov 199912468.9%-43.6%-26.5%
Sep 2001Oct 2001217.1%-43.3%-61.3%
Feb 2002Sep 200518476.9%-70.8%-69.8%
Feb 2010Feb 201013.0%-11.0%-78.5%
May 2010May 20115337.0%+29.7%-73.8%
Jun 2011Feb 20123724.1%+4.3%-79.8%
Mar 2012Apr 201246.2%+10.6%-79.9%
May 2012Jul 201256.5%+39.7%-80.1%
Oct 2013Oct 201311.9%+65.8%-79.9%
Dec 2013Jan 201419.1%+63.3%-78.4%
Jun 2016Sep 20176551.3%-29.0%-85.2%
Oct 2017Nov 201729.8%+35.0%-83.9%
Mar 2018May 2018811.0%+11.5%-84.8%
Nov 2018Mar 20191815.0%-23.4%-85.2%
May 2019Jul 20191224.8%-47.9%-83.7%
Aug 2019Oct 2019927.2%-50.1%-81.9%
Nov 2019Jan 20216461.4%-39.6%-80.6%
Apr 2021Apr 202112.0%-12.2%-83.2%
May 2021Jun 202142.0%-18.3%-83.3%
Nov 2021Jul 20223536.6%-26.2%-82.8%
Aug 2022May 20234139.3%-31.2%-81.6%
Jun 2023Jun 202310.3%+6.6%-79.9%
Jul 2023Feb 20243036.8%+17.4%-79.6%
Mar 2024May 2024818.6%-52.4%-78.4%
Jun 2024Jun 202412.4%-77.0%-79.3%
Oct 2024Ongoing75+81.9%Ongoing-80.4%
Average29+-10.8%

Frequently Asked Questions

Is MYGN below its 200-week moving average?

Yes. As of 2026-03-20, Myriad Genetics, Inc. (MYGN) is trading 72.2% below its 200-week moving average of $16.49. The current price is $4.58.

What is MYGN's 200-week moving average price?

Myriad Genetics, Inc.'s 200-week moving average is $16.49 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when MYGN drops below its 200-week moving average?

MYGN has crossed below its 200-week moving average 28 times in our data. The average one-year return after these crossings was -10.8%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 29 weeks on average.

Is MYGN a good value right now?

Here's what our data says about MYGN as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 25 (oversold). Free cash flow yield is 0.2%. Return on equity is -68.5%. Price-to-book is 1.2x. This is not a buy or sell recommendation — always do your own research.

How does MYGN compare to the S&P 500?

Over the past 29.6 years, $100 invested in MYGN would have grown to $81, compared to $1580 for the S&P 500. That's -0.7% annualized vs 9.8% for the index. MYGN has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20